Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Michael Harris-Love

Concepts (169)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Muscle Strength
15
2026
332
2.690
Why?
Myositis, Inclusion Body
5
2015
11
1.390
Why?
Gait
6
2025
316
1.360
Why?
Myositis
8
2015
57
1.340
Why?
Ultrasonography
4
2024
788
1.210
Why?
Muscle, Skeletal
12
2026
1795
0.960
Why?
Knee Joint
3
2025
439
0.910
Why?
Heel
2
2014
8
0.820
Why?
Quadriceps Muscle
3
2024
120
0.740
Why?
Dermatomyositis
6
2022
24
0.730
Why?
Osteoarthritis, Knee
2
2025
284
0.730
Why?
Multiple Sclerosis
2
2024
434
0.670
Why?
Lower Extremity
3
2024
449
0.660
Why?
Polymyositis
5
2014
13
0.650
Why?
Exercise Therapy
4
2013
486
0.590
Why?
Sarcoma, Kaposi
2
2009
82
0.470
Why?
Physical Therapists
1
2015
68
0.400
Why?
Isometric Contraction
2
2013
190
0.390
Why?
Range of Motion, Articular
2
2019
437
0.390
Why?
Ankle
1
2013
69
0.380
Why?
Predictive Value of Tests
5
2025
2097
0.320
Why?
Muscle Neoplasms
1
2009
9
0.300
Why?
Skin Neoplasms
2
2009
805
0.300
Why?
Arthralgia
1
2009
61
0.280
Why?
Middle Aged
17
2025
36359
0.270
Why?
Friedreich Ataxia
2
2009
77
0.260
Why?
Cross-Sectional Studies
4
2025
5875
0.250
Why?
Biomechanical Phenomena
2
2025
868
0.250
Why?
Renal Insufficiency, Chronic
2
2024
639
0.240
Why?
Physicians
1
2015
954
0.230
Why?
Aged
12
2026
26251
0.230
Why?
Severity of Illness Index
6
2014
2910
0.220
Why?
Male
23
2025
73014
0.210
Why?
Humans
35
2026
145625
0.210
Why?
Sarcopenia
1
2026
92
0.210
Why?
Foot Diseases
1
2004
17
0.200
Why?
Motor Activity
2
2009
701
0.200
Why?
Muscle Weakness
4
2013
92
0.200
Why?
Antibodies, Monoclonal, Murine-Derived
2
2014
96
0.190
Why?
Weight-Bearing
1
2004
186
0.190
Why?
Exercise Tolerance
2
2009
288
0.180
Why?
Leg
1
2004
243
0.180
Why?
Veterans
2
2025
1647
0.180
Why?
Adult
17
2024
40821
0.170
Why?
Kinetics
1
2025
1553
0.170
Why?
Resistance Training
1
2024
185
0.170
Why?
Activities of Daily Living
2
2009
438
0.170
Why?
HIV Infections
2
2009
3210
0.170
Why?
Bulbo-Spinal Atrophy, X-Linked
2
2011
3
0.160
Why?
Female
20
2024
79080
0.160
Why?
Physical Therapy Modalities
1
2004
341
0.150
Why?
Dance Therapy
1
2019
3
0.150
Why?
Immunosuppressive Agents
2
2017
824
0.150
Why?
Video Games
1
2019
25
0.140
Why?
Muscular Diseases
2
2015
110
0.140
Why?
Hand Strength
1
2018
145
0.130
Why?
Infliximab
1
2017
107
0.130
Why?
Dermatologic Agents
1
2017
69
0.130
Why?
Kidney Failure, Chronic
1
2022
582
0.120
Why?
Hypertension
1
2024
1270
0.110
Why?
International Cooperation
1
2005
192
0.110
Why?
Exercise
3
2024
2206
0.100
Why?
Reproducibility of Results
5
2015
3396
0.100
Why?
Accidental Falls
2
2014
226
0.100
Why?
Aging
1
2024
1983
0.100
Why?
Quality of Life
2
2009
3187
0.090
Why?
Terminology as Topic
1
2004
253
0.090
Why?
Immunologic Factors
1
2014
244
0.090
Why?
Disease Management
1
2005
649
0.080
Why?
Age Factors
1
2018
3321
0.080
Why?
Azasteroids
1
2011
5
0.080
Why?
Clinical Trials as Topic
1
2005
1062
0.080
Why?
Antirheumatic Agents
1
2013
309
0.080
Why?
Patellofemoral Pain Syndrome
1
2009
6
0.080
Why?
Ubiquinone
1
2009
36
0.070
Why?
Antibodies, Neoplasm
1
2009
34
0.070
Why?
Sensitivity and Specificity
1
2014
1992
0.070
Why?
Analysis of Variance
2
2008
1293
0.070
Why?
CD4 Lymphocyte Count
1
2009
280
0.070
Why?
L-Lactate Dehydrogenase
1
2008
112
0.070
Why?
Muscle Stretching Exercises
1
2008
18
0.070
Why?
Practice Guidelines as Topic
1
2005
1581
0.060
Why?
Child
9
2022
22638
0.060
Why?
Viral Load
1
2009
525
0.060
Why?
Radiography
1
2009
856
0.060
Why?
Treatment Outcome
8
2017
11744
0.060
Why?
Linear Models
1
2008
847
0.060
Why?
Immunoglobulins, Intravenous
1
2007
134
0.060
Why?
Diagnosis, Differential
1
2009
1500
0.050
Why?
Double-Blind Method
3
2017
2064
0.050
Why?
Walkers
1
2004
2
0.050
Why?
Geriatric Assessment
1
2026
238
0.050
Why?
Lymphedema
1
2004
22
0.050
Why?
Sickness Impact Profile
1
2003
67
0.050
Why?
Magnetic Resonance Imaging
2
2022
3917
0.050
Why?
Single-Blind Method
1
2024
312
0.050
Why?
Task Performance and Analysis
1
2004
203
0.050
Why?
Muscle Fatigue
1
2003
98
0.050
Why?
Rituximab
2
2014
208
0.050
Why?
Physical Fitness
1
2003
207
0.040
Why?
Regional Blood Flow
1
2024
507
0.040
Why?
Disability Evaluation
1
2003
297
0.040
Why?
Antibodies, Monoclonal
1
2009
1511
0.040
Why?
Adolescent
6
2013
22451
0.040
Why?
Follow-Up Studies
3
2011
5397
0.040
Why?
Fatigue
1
2022
362
0.040
Why?
Risk Factors
1
2014
10840
0.040
Why?
Cicatrix
1
2009
72
0.040
Why?
Muscular Atrophy
1
2009
87
0.040
Why?
Child, Preschool
3
2009
11888
0.040
Why?
Disease Progression
2
2011
2857
0.030
Why?
Independent Living
1
2019
114
0.030
Why?
Calcinosis
1
2009
231
0.030
Why?
Randomized Controlled Trials as Topic
1
2024
1754
0.030
Why?
Pilot Projects
2
2017
1878
0.030
Why?
Biomarkers
1
2008
4329
0.030
Why?
Prednisone
1
2017
229
0.030
Why?
Retrospective Studies
2
2009
17291
0.030
Why?
Drug Administration Schedule
1
2017
782
0.030
Why?
Cross-Over Studies
1
2017
612
0.030
Why?
Prognosis
1
2003
4331
0.030
Why?
Drug Therapy, Combination
1
2017
1034
0.030
Why?
Risk Assessment
1
2003
3678
0.030
Why?
Consensus
1
2005
465
0.020
Why?
Muscle Contraction
2
2008
427
0.020
Why?
Placebos
1
2013
190
0.020
Why?
Incidence
1
2009
2910
0.020
Why?
Observer Variation
2
2006
355
0.020
Why?
Aged, 80 and over
2
2019
8351
0.020
Why?
Inflammation
1
2024
2915
0.020
Why?
Dutasteride
1
2011
5
0.020
Why?
Walking
2
2009
544
0.020
Why?
Pain Measurement
1
2013
567
0.020
Why?
Obesity
1
2024
3123
0.020
Why?
Electrodiagnosis
1
2009
17
0.020
Why?
Gait Apraxia
1
2009
1
0.020
Why?
Erectile Dysfunction
1
2009
35
0.020
Why?
Neural Conduction
1
2009
92
0.020
Why?
Alemtuzumab
1
2009
15
0.020
Why?
Peripheral Nerves
1
2009
73
0.020
Why?
Lymphocyte Count
1
2009
166
0.020
Why?
Lymphocyte Depletion
1
2009
135
0.020
Why?
Glucocorticoids
1
2013
536
0.020
Why?
Androgens
1
2009
179
0.020
Why?
Proprioception
1
2008
32
0.020
Why?
Age of Onset
1
2009
557
0.020
Why?
Electromyography
1
2009
417
0.020
Why?
Injections, Intravenous
1
2007
197
0.020
Why?
Action Potentials
1
2009
498
0.010
Why?
Autoantibodies
1
2014
1498
0.010
Why?
Inflammation Mediators
1
2009
507
0.010
Why?
Surveys and Questionnaires
2
2009
6050
0.010
Why?
Antioxidants
1
2009
544
0.010
Why?
Infusions, Intravenous
1
2007
429
0.010
Why?
Testosterone
1
2009
419
0.010
Why?
Biopsy
1
2009
1073
0.010
Why?
Fractures, Bone
1
2011
431
0.010
Why?
Statistics, Nonparametric
1
2006
423
0.010
Why?
Physical Therapy Specialty
1
2006
55
0.010
Why?
Recovery of Function
1
2009
721
0.010
Why?
Antibodies, Monoclonal, Humanized
1
2009
992
0.010
Why?
CD8-Positive T-Lymphocytes
1
2009
929
0.010
Why?
CD4-Positive T-Lymphocytes
1
2009
1148
0.010
Why?
Dose-Response Relationship, Drug
1
2007
2018
0.010
Why?
Physical Examination
1
2003
236
0.010
Why?
RNA, Messenger
1
2009
2783
0.010
Why?
Gene Expression Regulation
1
2009
2591
0.010
Why?
Time Factors
1
2009
7079
0.010
Why?
Exercise Test
1
2000
634
0.010
Why?
Harris-Love's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)